Women’s health telehealth company Wisp has expanded into longevity care with a new Healthy Aging category – an explicit play to bring women into a market that has been largely shaped by male-centric biohacking culture.
The initial offering includes five clinician-guided treatments: glutathione (nasal spray and injection), NAD+ (nasal spray and injection), and low-dose naltrexone (LDN), focused on cellular energy, repair, and immune system recalibration. It also marks Wisp’s entry into peptides.
The launch is informed by a Wisp survey of nearly 2,000 women that surfaced a notable disconnect: 75% prioritize long-term health in their daily choices, but nearly half remain uncertain about which interventions actually work for the female body. And while 92% believe telehealth is vital for healthy aging, only 11% feel current digital tools give them a sense of control.
“As the telehealth market for treatments like NAD+ and glutathione becomes increasingly fragmented and expensive, women are being left behind,” said CEO Monica Cepak. “Women are navigating complex hormonal transitions and immune issues that don’t fit into a standard biohacking framework. We’re translating complex science into clear, clinician-guided plans that support women long before something escalates.”
Wisp’s roadmap includes mitochondrial support, cognitive health pathways, menopause-adjacent longevity care, and preventive diagnostics. The company is positioning itself as a lifecycle health partner rather than a transactional prescription platform – a strategic evolution from its origins in sexual and reproductive health.
